NCT04178642 The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol Status WITHDRAWN Phase PHASE2
NCT04172571 A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) Status COMPLETED Phase PHASE2
NCT04170556 Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) Status COMPLETED Phase PHASE1/PHASE2
NCT04170179 Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis Status UNKNOWN Phase PHASE2
NCT04169399 Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT Status UNKNOWN Phase PHASE2
NCT04168944 Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma Status UNKNOWN Phase PHASE2/PHASE3
NCT04167293 Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) Status UNKNOWN Phase PHASE2/PHASE3
NCT04162158 Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma Status UNKNOWN Phase PHASE1/PHASE2
NCT04161911 A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy Status COMPLETED Phase N/A
NCT04160897 Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis Status UNKNOWN Phase N/A
NCT04157985 Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors Status COMPLETED Phase PHASE3
NCT04157140 Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC Status UNKNOWN Phase PHASE2
NCT04152356 Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma Status UNKNOWN Phase N/A
NCT04152343 An Intraoperative Guidance Platform for Radio Frequency Ablation Status COMPLETED Phase NA
NCT04150874 Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE Status TERMINATED Phase EARLY_PHASE1
NCT04145141 National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer Status COMPLETED Phase N/A